The FDA said Neurochem Inc.'s Kiacta (eprodisate, formerly Fibrillex) is approvable for treating amyloid A (AA) amyloidosis, and the company's management is hopeful of clearing any final regulatory hurdles without additional trials. (BioWorld Today)
The FDA said Neurochem Inc.'s Kiacta (eprodisate, formerly Fibrillex) is approvable for treating amyloid A (AA) amyloidosis, and the company's management is hopeful of clearing any final regulatory hurdles without additional trials. (BioWorld Today)
WASHINGTON - Acting FDA Commissioner Andrew von Eschenbach might be one step closer to Senate approval following reports that the maker of the Plan B contraceptive product, Barr Pharmaceuticals Inc., agreed to file for over-the-counter status for women 18 and older. (BioWorld Today)
WASHINGTON - Acting FDA Commissioner Andrew von Eschenbach might be one step closer to Senate approval following reports that the maker of the Plan B contraceptive product, Barr Pharmaceuticals Inc., agreed to file for over-the-counter status for women 18 and older. (BioWorld Today)
